buthionine sulfoximine has been researched along with 3,4-dihydroxybenzalacetone in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gunjima, K; Hashida, K; Hori, O; Konishi, T; Matsugo, S; Nakamura, Y; Takakura, K; Tomiyama, R; Yamada, T | 1 |
1 other study(ies) available for buthionine sulfoximine and 3,4-dihydroxybenzalacetone
| Article | Year |
|---|---|
3,4-dihydroxybenzalacetone protects against Parkinson's disease-related neurotoxin 6-OHDA through Akt/Nrf2/glutathione pathway.
Topics: Buthionine Sulfoximine; Caffeic Acids; Cell Line, Tumor; Dose-Response Relationship, Drug; Glutathione; Humans; Neuroblastoma; Neuroprotective Agents; Neurotoxins; NF-E2-Related Factor 2; Oxidative Stress; Oxidopamine; Parkinson Disease; Protein Transport; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species | 2014 |